Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.11.2014 | main topic

Hepatocellular carcinoma

verfasst von: Maria Daoudaki, PhD, Ioannis Fouzas, MD, PhD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 21-22/2014

Einloggen, um Zugang zu erhalten

Summary

Hepatocellular carcinoma (HCC) is a heterogeneous tumor with many factors implicated in its development, with chronic infection and cirrhosis by hepatitis B virus (HBV) being the most prevalent. Cirrhosis due to metabolic syndrome, alcohol consumption, viral infection with hepatitis C virus (HCV) is also involved in its development. Treatment of HCC remains unsatisfactory. Therapeutic management for HCC includes liver transplantation, liver resection, ablation, chemoembolization, which depend on the tumor stage, liver function, and patient performance status. The involvement of different signaling pathways in the initiation and modulation of HCC development based on clinical and research data provided a strong rationale for the development of anti-cancer agents targeting key components of the pathways. The complexity of the tumor prevents the major goal of this therapeutic approach, since sorafenib, a multi-kinase inhibitor, is the only successful drug so far that belongs to the target directed therapy in advanced stage HCC.
Vorheriger Artikel Toward new targets for the diagnosis and treatment of malignant diseases
Nächster Artikel A short update on cancer chemoresistance
Literatur
1.
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
3.
Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988;61:1942–56.PubMedCrossRef
4.
Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:S294–308.PubMedCrossRef
5.
Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.PubMedCrossRef
6.
Lin CW, Lin CC, Mo LR, et al. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol. 2013;58:730–5.PubMedCrossRef
7.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef
8.
9.
10.
Weihrauch M, Benick M, Lehner G, et al. High prevalence of K-ras-2 mutations in hepatocellular carcinomas in workers exposed to vinyl chloride. Int Arch Occup Environ Health. 2001;74:405–10.PubMedCrossRef
11.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRef
12.
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436–44.
13.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
14.
Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef
15.
Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009;10:1314–9.PubMedCentralPubMedCrossRef
16.
Luedde T, Schwabe RF. NF-κB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8:108–18.PubMedCentralPubMedCrossRef
17.
Vucur M, Roderburg C, Bettermann K, et al. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma? Oncotarget. 2010;1:373–8.PubMedCentralPubMed
18.
Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–96.PubMedCrossRef
19.
Liu P, Kimmoun E, Legrand A, et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol. 2002;37:63–71.PubMedCrossRef
20.
Pang RW, Joh JW, Johnson PJ, et al. Biology of hepatocellular carcinoma. Ann Surg Oncol. 2008;15:962–71.PubMedCrossRef
21.
Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. Biomed Res Int. 2013;2013:1–14.CrossRef
22.
23.
Gao B, Wang H, Lafdil F, Feng D. STAT proteins – key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol. 2012;57:430–41.PubMedCentralPubMedCrossRef
24.
Ramakrishna G, Rastogi A, Trehanpati N, et al. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2:367–83.PubMedCentralPubMedCrossRef
25.
Kan Z, Zheng H, Liu X, et al. Whole-genome sequencing identifies recur-rent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422–33.PubMedCentralPubMedCrossRef
26.
Cleary SP, Jeck WR, Zhao X, et al. Identification of driver genes in hepa-tocellular carcinoma by exome sequencing. Hepatology. 2013;58:1693–702.PubMedCentralPubMedCrossRef
27.
Nault JC, Zucman-Rossi J. Genetics of hepatocellular carcinoma: the next generation. J Hepatol. 2014;60:224–6.PubMedCrossRef
28.
Chaiteerakij R, Roberts LR. Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: insights from next generation DNA sequencing. J Hepatol. 2013;58:1042–4.PubMedCrossRef
29.
Ji J, Wang XW. New kids on the block: diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther. 2009;8:1686–93.PubMedCrossRef
30.
Sun J, Lu H, Wang X, et al. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications. ScientificWorldJournal. 2013;1:1–37.
31.
Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol. 2012;2012:1–7.CrossRef
32.
Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocelular carcinoma. Dtsch Arztebl Int. 2014;111:101–6.PubMedCentralPubMed
33.
Shigoka M, Tsuchida A, Matsudo T, et al. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010;60:351–7.PubMedCrossRef
34.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18:997–1006.PubMedCrossRef
35.
Sherman M. Primary malignant neoplasms of the liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock’s diseases of the liver and biliary system. 12th ed. Chapter 35. Chichester: John Wiley & Sons Ltd; 2011. pp. 681–703.
36.
Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.PubMedCrossRef
37.
Schirmacher P, Bedossa P, Roskams T, et al. Fighting the bushfire in HCC trials. J Hepatol. 2011;55:276–7.PubMedCrossRef
38.
39.
Colombo M, Raoul JL, Lencioni R, et al. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol. 2013;25:639–51.PubMedCrossRef
40.
Lim C, Farges O. Primary malignant tumors of the liver. In: Garden OJ, Parks RW, editors. Hepatobiliary and pancreatic surgery. A companion to specialist surgical practice. 5th ed. Chapter 5. Edinburgh: Saunders-Elsevier; 2014. pp. 80–108.
41.
Edge SB, Byrd DR, Compton CC, et al. “AJCC Cancer Staging Manual”, American Joint Committee on Cancer. 7th ed. Springer; 2010.
42.
Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–28.PubMedCrossRef
43.
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRef
44.
The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751–5.
45.
Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002;94:1760–176.PubMedCrossRef
46.
Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–15.PubMedCrossRef
47.
Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol. 1999;31:133–41.PubMedCrossRef
48.
Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–15.PubMedCrossRef
49.
Smoot RL, Nagorney DM, Chandan VS, et al. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg. 2011;98:697–703.PubMedCrossRef
50.
Mergental H, Adam R, Ericzon BG, et al. Liver transplantation for unresectable hepatocellular carcinoma in normal livers. J Hepatol. 2012;57:297–305.PubMedCrossRef
51.
Palavecino M, Chun YS, Madoff DC, et al. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: perioperative outcome and survival. Surgery. 2009;145:399–405.PubMedCrossRef
52.
Vennarecci G, Laurenzi A, Santoro R, et al. The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg. 2014;38:1498–503.PubMedCrossRef
53.
Fouzas I, Sotiropoulos GC, Sgourakis G, et al. Five-year survival after monotherapy for hepatocellular carcinoma in the setting of cirrhosis. Transplant Proc. 2008;40:3204–5.PubMedCrossRef
54.
Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for HCC: an evidence-based analysis on 15 years of experience. Liver Transpl. 2011;17:S44–57.PubMedCrossRef
55.
Clavien PA, Lesurtel M, Bossuyt PM, et al. On behalf of the OLT for HCC consensus group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:11–22.
56.
Heckman JT, Devera MB, Marsh JW, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol. 2008;15:3169–77.PubMedCrossRef
57.
Fouzas I, Sotiropoulos GC, Lang H, et al. Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF criteria. Transplant Proc. 2008;40:3185–8.PubMedCrossRef
58.
Cho YK, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010;51:1284–90.PubMedCrossRef
59.
Poggi G, Montagna B, DI Cesare P, et al. Microwave ablation of hepatocellular carcinoma using a new percutaneous device: preliminary results. Anticancer Res. 2013;33:1221–7.PubMed
60.
Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11:790–800.PubMedCrossRef
61.
62.
Llovet JM, Ricci S, Mazzaferro V, et al. SHARP investigators study group sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRef
63.
64.
Metadaten
Titel
Hepatocellular carcinoma
verfasst von
Maria Daoudaki, PhD
Ioannis Fouzas, MD, PhD
Publikationsdatum
01.11.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 21-22/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0296-7

Weitere Artikel der Ausgabe 21-22/2014

Epithelial ovarian cancer - more data, more questions?

  • main topic

Translational hematology

  • Review

Erratum to: Hepatocellular carcinoma

  • Erratum

Interplay of drug metabolizing enzymes with cellular transporters

  • Review

Expression and putative functions of melatonin receptors in malignant cells and tissues

  • main topic

Toward new targets for the diagnosis and treatment of malignant diseases

  • editorial